DIRECT EVIDENCE FOR HAGEMAN FACTOR (FACTOR XII) ACTIVATION BY BACTERIAL LIPOPOLYSACCHARIDES (ENDOTOXINS) by Morrison, David C. & Cochrane, Charles G.
DIRECT  EVIDENCE  FOR  HAGEMAN  FACTOR  (FACTOR XII) 
ACTIVATION  BY  BACTERIAL  LIPOPOLYSACCHARIDES 
(ENDOTOXINS)*. 
BY  DAVID  C.  MORRISON  AND CHARLES  G.  COCHRANE 
(From the Department of Experimental Pathology, Scripps Clinic  and Research 
Foundation, La Jolla, California  92037) 
(Received for publication 4 April 1974) 
Bacterial lipopolysaccharides (LPS)  I or endotoxins elicit a variety of host responses, 
the  combination  of  which  result  in  the  deposition of  fibrin  in  capillaries and  dis- 
seminated intravascular coagulation  (DIC).  These various host responses  to  endo- 
toxins have recently been  summarized  (1)  and  include: (a)  aggregation of platelets 
and  release of platelet factor 3;  (b)  activation of Hageman  factor;  (c)  inhibition of 
fibrinolysis; (d) aggregation of leukocytes and release of intracellular constituents; (e) 
stimulation of the a-adrenergic receptor sites in  the kidney; and  (f)  impairment of 
reticuloendothelial system  function.  Whereas  there  exists  substantial  experimental 
evidence to support most of these effects of endotoxin, the evidence for the initiation 
of the intrinsic clotting system by the direct activation of Hageman factor by endo- 
toxin has been limited and indirect. 
Considerable indirect evidence has inferred that Hageman factor may be activated 
after  the  injection  or  release  of  endotoxin.  Patients  in  shock  from  gram-negative 
bacteremia, but not from hemorrhagic shock, have been estimated to have decreased 
levels of both Hageman factor and prekallikrein (2). Increased levels of plasma kinins 
have, in addition, been demonstrated within 30  rain of the intravenous injection of 
purified LPS  into  human  volunteers  (3).  Indirect evidence  in  vitro  for  endotoxin- 
induced activation of Hageman factor has been demonstrated by the experiments of 
Rodriquez-Erdmann  (4),  who  showed  that  LPS  significantly altered  the  thrombo- 
plastin-generating times in plasma but had no effect on purified prothrombin. 
Injections of endotoxin in rabbits have led to a diminution of circulating Hageman 
factor levels (5, 6). However, the reduction was likely secondary to other effects of the 
endotoxin since treatment with vitamin K analogues, or depletion of granulocytes pre- 
vented the fall of Hageman factor levels. 
That  the activation of Hageman factor in vivo may participate in DIC has been 
inferred  from  several studies.  Injection  of  the  Hageman  factor  activators  sodium 
stearate or ellagic acid into rabbits induced DIC when accompanied by administration 
* This is publication 826 from the Department of Experimental Pathology, Scripps Clinic 
and Research Foundation, La Jolla, Calif. 
This work was supported by the U.S. Public Health Service grant AI-07007 and the Amer- 
ican Heart Association. 
1  Abbreviations used in this paper: BALe, benzoyl arginine ethyl ester; DIC, disseminated 
intravascular coagulation; KDO,  2-keto-3-deoxyoctanoic  acid;  LPS,  bacterial lipopolysac- 
charides; OMTI ovomucoid trypsin inhibitor. 
THE  JOURNAL OF  EXPERIMENTAL MEDICINE • VOLUME 140,  1974  797 798  HAGEMAN  FACTOR  ACTIVATION  BY  LIPOPOLYSACCHARIDES 
of epsilon-aminocaproic  acid (to inhibit fibrinolysis) and norepinephrine (to stimulate 
a-adrenergic receptor sites in the kidney) (7, 8). In another study, injection of acti- 
vated Hageman factor into pregnant (fibrinolysin inhibited) rats, when accompanied 
by  norepinephrine and  inosithin (a  substitute for  platelet  factor  3)  produced  the 
generalized Schwartzman reaction in six of seven animals (9). Further administration 
of endotoxin to fowl which are naturally deficient in Hageman factor, failed to elicit 
DIC, although fibrin was precipitated intravascularly  upon administration  of thrombo- 
plastin (10). Hereditary deficiency of factor VII of the extrinsic clotting system in dogs 
also failed to prevent a fall in fibrinogen levels after injection of endotoxin, suggesting 
participation of the intrinsic clotting system (1 l). 
In contrast to the above experiments, data also indicate participation of the extrinsic 
clotting system  in DIC.  Rabbits, depleted  of  factor  VIII of  the  extrinsic clotting 
system with heterologous antibody, demonstrated a fall in fibrinogen levels after in- 
jection of endotoxin that equalled the drop found in normal rabbits. In fact, one of the 
factor VIII-depleted rabbits developed a generalized Schwartzman reaction (12). The 
use of lysozyme to block contact activation of Hageman factor in vivo failed to block 
DIC  of  the generalized Schwartzman reaction in endotoxin-treated rabbits (5),  al- 
though lysozyme, together with vitamin K analogues did inhibit DIC after the injec- 
tion of liquoid (1, 13). 
If  endotoxin  (bacterial  lipopolysaccharide,  LPS)  is  capable  of  initiating 
clotting via the intrinsic clotting system it is essential to determine which com- 
ponent in the series is activated by the LPS.  In this report,  we demonstrate 
that purified LPS can activate directly purified precursor Hageman factor, the 
initial component of the intrinsic clotting system, that the interaction of LPS 
and precursor Hageman factor results in the formation of a  complex between 
these two molecules, and that this complex possesses the capacity to activate 
prekallikrein. 
Materials and Methods 
Plasma Proteins.--Both  rabbit and human Hageman factor were purified in precursor form 
by methods previously published (14). The resulting Hageman factor failed to activate  prekal- 
likrein unless exposed to activators. All Hageman factor preparations were used at a concen- 
tration of 30 #g/ml, i.e., at approximately the concentration found in whole human plasma. 2 
For some experiments, purified human precursor Hageman factor was labeled with  ~25I by 
the procedure of McConahey and Dixon (15). The purity of these preparations has been pre- 
viously described.  2 Purified rabbit prekallikrein was also prepared  as  previously described 
(14), and was used at a concentration of 12.5 #g/ml (1,000 mU/ml). 
Plasma.--Hageman factor-deficient plasma was generously donated by Mrs. Gunda Hiatt. 
Blood was collected into acid citrate anticoagulant (13.65 g citric acid, 25.0 g NaCitrate,  20.0 
g dextrose, pH 4.7; 1 part to 6 parts blood) and the plasma was separated from the formed ele- 
ments by centrifugation at 4,000 rpm for 30 rain and stored at --70°C until just before use. 
Bacteria.--Escherichia coli 0111 :B4 was grown in minimal medium as previously described 
(16). The epimeraseless mutant of this strain (J-5) obtained from Dr. Loretta Leive, as well 
2 Revak, S. D., C. G. Cochrane, A. R. Johnston, and T. E. Hugli. 1974. Structural changes 
accompanying enzymatic activation  of human Hageman factor.  Manuscript  submitted  for 
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as the heptose-deficient mutant from Salmonella  minnesota  (R595)  obtained  from  Dr.  John 
Ryan were grown with aeration in trypticase soy broth  (Baltimore Biological Laboratories, 
Baltimore, Md.). Cells were harvested by centrifugation and washed twice with 0.85% sodium 
chloride. 
Lipopolysaccharides.--LPS  was extracted from 0111 :B4 by the phenol-water procedure of 
Westphal and Jann (17) and purified as previously described (18, 19). This preparation of LPS 
was then further fractionated by column chromatography on Sepharose 4B, (Pharmacia Fine 
Chemicals, Inc., Piscataway, N. J.), as described elsewhere, 3 into two fractions, LPS-I and 
LPS-II containing approximately I% and 10% by weight of lipid A, respectively. The LPS 
fractions prepared by this method have been estimated to contain less than 1% protein and 
5% nucleic acid. 3 Both of these LPS fractions have been demonstrated to be lethal to mice, 3 
cause DIC in rabbits,* and to be mitogenic for B  lymphocytes (20). LPS from the mutant 
strains J-5 and R-595 were extracted and purified by the phenol-petroleum ether-chloroform 
procedure of Galanos et al.  (21). These latter preparations were insoluble in water and were 
briefly sonicated to prepare a  fine suspension immediately before use. Lipid A was prepared 
from purified preparations of 0111 : B4-LPS by mild acid hydrolysis in 0.1 N HCI for 25-35 min 
at  100°C.  The precipitated lipid A was then solubilized by  the addition of  triethylamine to 
0.1% suspensions of lipid A, and the solubilized lipid A then dialyzed extensively against dis- 
tilled water (22). 
Chemical Assays.--The somatic O-antigen determinant of E. coli 0111 : B4 contains a dideox- 
yhexose (colitose) which is specifically and conveniently measured  by  the thiobarbituric acid 
assay described by Cynkin and Ashwell (23), after mild acid hydrolysis of LPS.  If the hy- 
dolysis conditions are modified (0.01 N H2SO4 instead of 0.2 N H2SO4)  and the periodate oxi- 
dation carried out for 60 min at 0°C instead of 20 rain at 55°C,  the reaction with colitose is 
effectively suppressed and this same assay may then be used to estimate relative levels of the 
eight  carbon  saccharide  2-keto-3-deoxyoctanoic  acid  (KDO)  (the  specific  carbohydrate 
linkage between the lipid A portion of the LPS molecule and the heptose backbone of the poly- 
saccharide region) after correction for residual reactive colitose. 4 This assay is a highly sensi- 
tive and  extremely specific assay  for dideoxyhexoses which are found almost exclusively in 
LPS (23). 
Determination  of Hageman  Factor Activation.--For  all of the experiments described in the 
following paragraphs,  activation is defined as  the conversion of  the enzymatically inactive 
precursor Hageman factor to a form in which it may interact with one or more of  its natural 
substrates. All assays were performed in plastic tubes to avoid the spontaneous activation of 
Hageman factor by glass. Two methods have been used to estimate the ability of LPS to acti- 
vate purified precursor Hageman factor. In the first, preparations of LPS plus Hageman factor, 
in a final vol of 100/A in Tris-buffered saline (0.01 M Tris, 0.14 M NaCI, pH 7.4) after incuba- 
tion for 20 min at 37°C, were added to purified preparations of rabbit prekallikrein (1.25 #g in 
100/~1)  (24)  and incubated for a  further 20-rain period.  Conversion of prekallikrein to the 
active enzyme was assayed after the addition of 3.0 ml of 1 mM benzoyl arginine ethyl ester 
(BAEe). Enzymatic activity was determined by cleavage of the ethyl ester as estimated by a 
change in absorbance at 253 nm. LPS alone was shown to have no effect on either prekallikrein, 
BAEe, or a mixture of the two. In the second method, the ability of LPS-activated Hageman 
factor to reduce the clotting time of XII-deficient plasma was determined (14). 
Sucrose Gradient  Ultracentrifugation.--Preparations  of LPS, Hageman factor, or a mixture 
of the two were layered onto 5-20% linear sucrose gradients and centrifuged in the Spinco 
3 Morrison, D. C. and L. Leive. 1974. Two fractions of lipopolysaccharide from Escherichia 
coli 0111 : B4 as prepared by two extraction procedures. Manuscript submitted for publication. 
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Model L  preparative  ultracentrifuge  (Beckman Instruments,  Inc.,  Spinco Div.,  Palo Alto, 
Calif.) for 15 h at 30,000 rpm using an SW 50 rotor. Fractions of approximately 0.35 ml were 
then collected from the bottom of the tube and were assayed by addition of 0.05-ml  aliquots 
of the fractions to 0.1 ml prekallikrein as noted above, or by treating a similar volume aliquot 
with 0.1 #g trypsin  (Worthington Biochemical Corp., Freehold, N. J.) for 20 rain at 37°C to 
activate  Hageman  factor,  inhibiting  the  trypsin  with  25  /~g ovomucoid  trypsin  inhibitor 
(OMTI, Worthington Biochemical Corp.) and then assaying the fraction for its ability to acti- 
vate prekallikrein. To measure LPS in the gradient fractions, aliquots were dialyzed exten- 
sively vs. distilled water before assaying levels of colitose, which reflects the concentration of 
LPS (sucrose  in high concentration interferes with this assay). 
Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis.--Aliquots of 125I-tabeled  hu- 
man  Hageman  factor were electrophoresed and  assayed  for radioactivity as described  else- 
where (25). 
RESULTS 
The Direct Activation of Hageman Factor by LPS.--To determine the relative 
ability of LPS to activate Hageman factor, increasing concentrations  of LPS-I 
and  LPS-II  were  incubated  with  a  constant  amount  of  purified  rabbit  Hage- 
man  factor  and  the  resulting  ability  of  activated  Hageman  factor  to  convert 
prekallikrein  to its active form then  measured.  The results  of this experiment, 
shown in Fig.  1, demonstrate  that  although  both preparations  of LPS can acti- 
vate Hageman  factor,  LPS-II  is more  than  10-fold more efficient than  LPS-I. 
It has been demonstrated 3 that LPS-II contains significantly higher amounts of 
lipid A  on a  weight basis than does LPS-I. 
Demonstration  of Lipid A  as the Active  Principle  of the LPS Molecule.--The 
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FIG. 1.  The activation of Hageman factor by LPS. Increasing  amounts  of purified  LPS 
from E. coli 011 l:B4 containing approximately 10% lipid A (LPS-II) or 19~ lipid A (LPS-I) 
were added to 0.3 #g of purified rabbit Hageman factor in a final vol of 100 #1. After incuba- 
tion for 20 min at 37°C,  1.25 #g of purified  prekallikrein in 100 #l of Tris-buffered saline was 
added and the mixture incubated an additional 20 min. Then 3.0 ml of 1 mM BAEe was added 
and the change in absorbance measured as a function of time of incubation at 37 °. The circles 
and triangles represent individual experiments. DAVID  C.  MORRISON  AND  CHARLES  G.  COCHRANE  801 
fact  that  LPS-II  is biochemically  more  potent  than  LPS-I  suggests  that  the 
lipid A region of the LPS molecule may be responsible for Hageman factor acti- 
vation (see Fig.  2). To examine this question further,  the lipid A portion of the 
LPS-II molecule was chemically removed by mild acid hydrolysis.  The rate of 
disappearance  of  the  ability  of  the  treated  LPS  to  activate  rabbit  Hageman 
factor was then compared with the rate of removal of lipid A as measured by the 
appearance of free KDO. Hydrolysis was carried out in 0.01  N  sulfuric acid for 
various times at 100°C. To assay for free KDO, samples were then chilled rapidly 
and assayed by the thiobarbituric  acid assay as described  in the Materials and 
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FIG. 2.  The schematic structure of LPS. The basic structure of the LPS of E. coli 0111 :B4 
consists of a repeating polysaccharide portion and a lipid portion (lipid A). The polysaccharide 
composition of the O-antigen is varied within a given species of bacteria,  the core polysaccha- 
ride is common within  a species of bacteria but varies between bacterial  species and the lipid 
A and KDO is common to all bacterial  species. The chemical structure of the preparations of 
LPS obtained from the complete and mutant strains of bacteria used in these experiments  is 
indicated  (E. cdi 0111 :B4, LPS-I, n ~  10, LPS-II, n ~  2). 
i 
Methods.  To determine  Hageman  factor  activation,  samples were neutralized 
with NaOH, the lipid A extracted with chloroform, and the partially hydrolyzed 
remaining  LPS  assayed for ability to activate Hageman factor at several con- 
centrations  of LPS.  The results of this  experiment,  shown  in  Fig.  3  a, demon- 
strate that very short periods of hydrolysis are sufficient to increase the amount 
of LPS required  for Hageman factor activation.  By meitsuring  the quantity  of 
LPS,  after  acid  hydrolysis,  required  to  activate  approximately  50%  of  the 
Hageman  factor,  an  approximate  correlation  is  apparent  between  the  loss  of 
Hageman factor-activating  capacity and the  appearanc~ of relative amount  of 
free KDO (Fig. 3 b). 
In order to determine  more accurately  the role of lipid A  and other portions 
of the LPS molecule in  the activation of Hageman factor, preparations  of LPS 
from mutant bacteria,  as well as purified lipid A were prepared (see Fig. 2). The 
LPS from the  J-5 strain of E. coli does not  contain O-antigenic polysaccharide 802  HAGEMAN  FACTOR ACTIVATION  BY  LIPOPOLYSACCHARIDES 
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FIG. 3.  The removal of lipid A by mild acid hydrolysis and its effect on Hageman facto 
activation.  Samples of LPS-II  were hydrolyzed in 0.01 N  H2SO4 at 100°C for various times 
The generation of liberated lipid A was estimated  by the appearance of free KDO.  After ex- 
traction of the lipid A into CHCIs, the remaining polysaccharide was assayed  for its ability 
to activate Hageman factor as described in the legend to Fig.  1.  (a) The activation  of rabbit 
Hageman factor by increasing amounts of partially hydrolyzed LPS-II.  (b) The appearance of 
free KDO and the approximate amount of partially hydrolyzed LPS-II required to give 50% 
of maximal Hageman factor activity are plotted as a function of time of hydrolysis of LPS-II. 
and contains a high concentration of lipid A. The R-595 mutant contains only 
the KDO trisaccharide and lipid A. Both of these LPS preparations activated 
Hageman factor with respect to its action on prekallikrein. While the)' were less 
active than LPS-II, accurate comparisons are difficult owing to  the fact that 
LPS-II is soluble in water, while the other two are obtained as insoluble aggre- 
gates.  Further  evidence for the  action of lipid A  on Hageman factor was ob- 
tained with purified lipid A which was found to be a highly effective activator of 
Hageman factor (see Fig. 4). 
Initiation of the Intrinsic Clotting System by Hageman Factor Treated with LPS. 
--As the above experiments indicate that LPS  (and in particular lipid A) can 
activate Hageman factor with respect to its ability to convert prekallikrein, it 
was also of interest to examine the ability of LPS to activate Hageman factor to 
nitiate clotting. For these experiments, purified human Hageman factor was in- 
cubated with various preparations of LPS and the mixture tested for clot pro- 
motion in Hageman factor-deficient plasma. The results of these experiments, 
shown in  Fig.  5,  demonstrate that both LPS preparations tested  had  the ca- DAVID  C.  MORRISON  AND  CHARLES  G.  COCHRANE  803 
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FIG.  4.  The activation of Hageman factor by isolated lipid A. Increasing amounts of lipid 
A, isolated from E. coil 0111 : B4 LPS-II, were incubated with purified human Hageman factor 
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Fzo. 5.  The influence of LPS-activated Hageman factor on the clotting of factor XII-de- 
ficient plasma. Approximately 0.3 #g of purified human Hageman factor were incubated with 
increasing concentrations of either S. minnesota  R-595-LPS or 0111 :B4-LPS-II for I0 rain at 
37°C in a  final vol of 100 ~1. Then 50 #1 of XII-deficient plasma were added and incubation 
continued for an additional 5 rain. Finally 50 #l of a 1 : 50 dilution of cephalin containing 10 mM 
calcium were added and the time for clot formation determined. Each time point shown is the 
average of triplicate clot time determinations. 
pacity to decrease clotting times in XlI-deficient plasma by activating purified 
precursor Hageman factor, and that responses were concentration dependent. 
Further, with only one exception (5 #g of LPS-II) LPS alone did not affect the 
clotting times of Hageman factor-deficient plasma, although the reason(s) for 
this are not known. The absence of a demonstrable decrease in clotting time of 
Hageman factor incubated in the absence of LPS demonstrates that the Hage- 
man factor was essentially in precursor form. 804  HAGEMAN  FACTOR  ACTIVATION  BY  LIPOPOLYSACCHARIDES 
Demonstration of Binding of Hageman Factor to LPS.--Purified human Hage- 
man factor (supplemented with  trace ~25I-labeled human Hageman factor) was 
incubated with approximately 100/~g of LPS-II at 37°C for 20 rain. This mix- 
ture was then sedimented in a 5-20% linear sucrose gradient as described in the 
Materials  and Methods.  Both LPS-II and  ~25I-labeled  Hageman  factor  incu- 
bated alone were also centrifuged as controls. The results of this experiment are 
shown  in  Fig.  6.  Hageman factor,  incubated  in  the  absence of LPS-II, sedi- 
mented near the top of the gradient,  (Fig. 6 a),  at its characteristic 4.5S  rate. 
The sedimented Hageman factor contains no spontaneous activity, but could 
be activated by incubation with trypsin as shown. LPS-II and Hageman factor 
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FIG.  6.  The demonstration of Hageman factor binding to LPS. Samples containing 100 #g 
of LPS-II, approximately 1 #g of 131I-labeled human Hageman factor or a mixture of the two 
were incubated in a final vol of 200 #] for 20 rain at 37°C. These samples were then layered onto 
5-20c7o linear sucrose gradients and centrifuged for 15 h at 90,000 X g. Aliquots, collected from 
the bottom of the tube, were assayed, where appropriate, for the presence of 1311, spontaneous 
Hageman factor activity, Hageman factor activatible by trypsin, ability to activate purified 
human Hageman factor, or the LPS-specific sugar colitose.  (a)  The sedimentation profile of 
Hageman factor. Gradient aliquots were assayed for 131I (solid curve), spontaneous Hageman 
factor activity, or Hageman factor activity after treatment with trypsin. (b) The sedimentation 
profile of Hageman factor. Gradient aliquots were assayed for 1311 (solid curve), spontaneous 
Hageman factor activity, or LPS (dashed curve). (c) The sedimentation profile of LPS. Gradi- 
ent fractions were assayed for LPS (dashed curve) and for their capacity to activate 0.3 #g of 
purified human Hageman factor. DAVID  C.  MORRISON  AND  CHARLES  G.  COCHRANE  805 
preincubated together at 37°C  (Fig. 6 b)  sedimented together as a  complex in 
the region of the LPS-II peak,  5 and  the prekallikrein-activating capacity was 
associated  with  the LPS-Hageman  factor complex. This  experiment demon- 
strated that Hageman factor does bind to, and is, in turn, activated by the LPS 
molecule.  The LPS-II preparation, incubated without Hageman factor (Fig. 
6 c), sedimented near the bottom of the gradient. Only those fractions which 
contained LPS (as determined by colitose) had the capacity to activate Hageman 
factor added to the gradient fractions, confirming that it is the LPS-II, and not 
a contaminant in the LPS-II preparation, which was responsible for the activa- 
tion of Hageman factor. 
When equivalent preparations of LPS-II were incubated with  radiolabeled 
Hageman factor, and then subjected to SDS polyacrylamide gel electrophoresis, 
no cleavage of the Hageman factor molecule could be demonstrated  (see Fig. 
7 a). Both LPS activated Hageman factor and control Hageman factor migrated 
as superimposable radiolabel peaks at a position of approximately 80,000 tool 
wt. The binding of Hageman factor fragments to LPS can be excluded by the 
observation  3 that LPS-II is dissociated in SDS to approximately 90,000.  If all 
of the Hageman factor fragments remained bound to the LPS it would have an 
aggregate mol wt of 170,000 and would not migrate into the gel. It may thus be 
concluded that  LPS  activation of Hageman factor does not  involve peptide 
bond cleavage. This contrasts to the fluid phase activation observed with tryp- 
sin, kallikrein, or plasmin  (25)  in which Hageman factor is cleaved into lower 
molecular weight fragments during the activation (Fig. 7 b). 
Inhibition  of Hageman Factor Activation  by LPS.--A consistent reversal of 
the decrease in clotting times has been observed when high concentrations of 
LPS  have  been  used  to  activate  Hageman  factor  (see  Fig.  5).  To  examine 
whether a parallel observation could be obtained in the prekallikrein activating 
system, preparations of purified human Hageman factor were incubated with 
high  concentrations of LPS  (relative  to  that  required  to  activate Hageman 
factor). When these preparations were then tested for prekallikrein conversion, 
a pronounced inhibition was also observed (see Fig. 8 a). 
This inhibition of activity could occur as a result of either an interaction of 
LPS with Hageman factor or with prekallikrein. In order to assess  the relative 
contribution of each of these factors to the LPS-induced inhibition, the concen- 
tration of both Hageman factor and prekallikrein in the reaction mixture were 
varied independently. The results of these experiments are shown in Fig.  8 a 
and 8 b. In Fig. 8 a, the LPS-induced activation inhibition response is shown for 
three concentrations of Hageman factor. There  appears  to  exist  a  stoichio- 
metric relationship between the  amount of Hageman factor present  and  the 
amount of LPS required to inhibit. For example, when the amount of Hageman 
5 As LPS-II has an approximate sedimentation value of llS and Hageman factor about 
4.5S, the binding of Hageman factor to the LPS molecule  would not be expected to substan- 
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Fzo. 7.  SDS acrylamide gel electrophoresis  of activated Hageman factor. Samples of 131I- 
labeled human Hageman factor  were activated  by either trypsin or by LPS. After electro- 
phoresis, gels were sectioned into  1 mm fractions and  the  radioactivity  in  each section 
determined. (a) The solid phase activation of Hageman factor by LPS. (b) The fluid phase ac- 
tivation of Hageman factor by trypsin. 
factor is  increased  by  2.5  or  6.3,  the  amount of LPS required  to give  an  in- 
hibition of  50%  is  increased  from  50  jzg to 120  ~g and 300  #g,  respectively, 
suggestive that the LPS may be directly inhibiting Hageman factor activation. 
In a second experiment, the amount of Hageman factor was maintained con- 
stant and two concentrations of purified prekallikrein were used.  As shown in 
Figure 8 b, an increase in the amount of prekallikrein added to the incubation 
mixture partially reversed the inhibitory effect of LPS. However, at the higher 
concentrations of LPS, as the reversal of inhibition was not  stoichiometrically 
correlated with the amount of prekallikrein added (twofold increase in rate with 
fourfold increase in  prekallikrein),  some inhibitory  effect of LPS  on prekalli- 
krein is also suggested. 
To examine further the nature of the inhibition of Hageman factor activation 
at  high  concentrations  of  LPS,  an  experiment  was  performed  to  determine 
whether the inhibited  Hageman factor could still be activated by fluid phase 
activators. Human Hageman factor was incubated with various concentrations 
of LPS for 20 min at 37°C, after which the incubation mixture was divided into 
two aliquots.  The Hageman factor in  one aliquot  was then  further  activated 
with  trypsin for  10 min  at  37°C,  after which  the  reaction  was stopped with 
OMTI. The other aliquot was treated simultaneously with trypsin and trypsin 
inhibitor.  Both aliquots were than tested for their ability to activate prekalli- 
krein.  The  results  of this  experiment,  shown  in  Table I, suggest  that  nonin- 
hibitory  concentrations  of  LPS  (10 #g)  do  not  inhibit  further  activation  of DAVID  C.  MORRISON  AND  CHARLES  G.  COCHRANE  807 
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FIG. 8.  The activation/inhibition of Hageman factor as a  function of LPS concentration. 
The capacity of either Hageman factor or prekallikrein to reverse the inhibition observed at 
high concentrations of LPS was  examined.  The experimental details were as  noted in the 
legend to Fig. 1 except where noted. (a) Activation/inhibition  as a function of Hageman factor 
concentration. Increasing concentrations of LPS-II were incubated with 0.2 #g, 0.5 #g, and 
1.25 #g of purified human Hageman factor in a  final vol of 100/zl. Then 1.25 #g of  purified 
rabbit prekallikrein in 100 #1 were added and activation determined as described in Fig. 1. (b) 
Activation/inhibition as a  function of prekallikrein concentration. Approximately 0.3 #g of 
purified human Hageman  factor were incubated with increasing concentrations of LPS-II. 
Then 0.63 and 2.5 #g of purified rabbit prekallikrein in 200 #1 were added and activation de- 
termined as described in Fig. 1. 
TABLE  I 
0111:B4 -  LPS II 
/zmol BAEe hydrolyzed/min/cm  3 
+ Trypsin  -- Trypsin 
0  5.59  0 
10 #g  5.22  3.08 
50 #g  0.52  0.16 
100 #g  0.20  0.28 
Hageman  factor by trypsin but that inhibitory concentrations of LPS  (100 #g) 
interfere with the action of trypsin on the Hageman  factor molecule. 
DISCUSSION 
We have demonstrated  that Hageman  factor can be activated by incubation 
with purified preparations of LPS to initiate both the intrinsic clotting and the 808  HAGEMAN  FACTOR  ACTIVATION  BY  LIPOPOLYSACCHARIDES 
kinin-forming pathways. As has been demonstrated for most of the other bio- 
logical properties of LPS, capacity to activate Hageman factor appears to reside 
in the lipid A region of the molecule (see Fig. 2). We have demonstrated this by 
showing (a) that preparations of LPS rich in lipid A have a greater potential for 
activation of Hageman factor than those poor in lipid A; (b) that LPS mutants, 
lacking the complete carbohydrate moiety, but possessing the lipid A moiety 
still have the  capacity to  activate Hageman factor; (c) that  the  time-course 
of removal of lipid A from  the  polysaccharide backbone was  approximately 
paralleled by loss of ability to activate Hageman factor; and (d) that isolated 
purified lipid A is an extremely potent activator of Hageman factor. 
High concentrations of LPS have been demonstrated to inhibit the activity of 
Hageman factor-related systems, and the results of several experiments suggest 
that the LPS-induced inhibition may be the result of a direct interaction between 
LPS and Hageman factor. In addition to the observation that high concentra- 
tions of LPS can inhibit two distinct functions mediated by Hageman factor, 
e.g. initiation of clotting and activation of prekallikrein, this latter inhibition 
can be stoicheometrically correlated  to  the  ratio of Hageman factor to LPS. 
The model of direct inhibition of Hageman factor is further suggested by ex- 
periments which show that LPS-inhibited Hageman factor is incapable of being 
further activated in the fluid phase by trypsin, whereas Hageman factor which 
has been only partially activated by LPS may still be further activated by 
trypsin. The concept of the inactivation of Hageman factor by LPS through 
direct contact is supported by the observation that Hageman factor forms a 
complex  with  LPS. 
It has been known for some time that Hageman factor may be activated by 
contact with negatively charged surfaces such as glass,  kaolin, celite, etc. LPS 
has been shown to have a  net negative charge at physiological pH  (26).  In 
addition, the lipid A region, which consists of a diglucosamine with both ester-, 
and amide-linked fatty acids, also contains negatively charged pyrophosphate 
groups (Fig. 9)  (27). It is, therefore, attractive to consider these charged phos- 
phates as being responsible for the activation of Hageman factor. Alternatively, 
preparations  of fatty acids have  also been  shown  to  affect Hageman factor 
(28-30)  and as the lipid A region is rich in fatty acids, it may be this portion of 
the lipid A which is responsible for the activation. 
0  CH2  /C'H2  0 
OoIH  )  NH  0 
', 
I~OO)  R = Fatty Acid 
Fzo. 9.  Diagrammatic structure of lipid A. As defined by Reitschel et al. (27). DAVID C.  MORRISON AND  CHARLES G.  COCHRANE  809 
The demonstration of a stable complex between the Hageman factor mole- 
cule  and  the  LPS  molecule  suggests  that  this  mechanism  of  activation  is 
analogous to the solid-phase activation as compared to the fluid-phase activa- 
tion initiated by enzymatic cleavage of the molecule (25).  The experimental 
data showing no significant change in  the molecular weight of the  Hageman 
factor molecule after LPS  activation  support  the  hypothesis originally pro- 
posed by Hardisty and Margolis (31)  that binding of Hageman factor to nega- 
tively charged surfaces causes a conformational change in the molecule which 
then renders it enzymatically active. In the case of LPS it may be the lipid A 
region  of the LPS molecule  (and  perhaps  the  negatively charged phosphate 
groups of this portion of the LPS molecule or the covalently linked fatty acids) 
which can bind the Hageman factor. This binding then causes a conformational 
change,  but  not  covalent  cleavage,  of  the  molecule which  is  then  rendered 
capable of at least two activities, initiation of clotting and activation of prekal- 
likrein. 
These results support the concept that bacterial endotoxins are capable of 
initiating activity of the intrinsic clotting system as well as the kinin-forming 
and perhaps also the fibrinolytic systems. The soluble LPS used in the present 
experiments was found to be one of the most active agents we have encountered 
among solid-phase activators in  its  ability  to convert Hageman factor to  an 
active state. The participation of this mechanism in disseminated intravascular 
coagulation remains to be defined. 
SUMMARY 
Purified precursor Hageman factor has been demonstrated to bind to soluble 
bacterial  lipopolysaccharide  (LPS,  endotoxin)  isolated  from  Escherichia  coli 
0111:B4,  and this complex has been shown to have the capacity to convert 
prekallikrein  to its  active form. In  addition,  LPS-activated Hageman factor 
substantially  reduces clotting times in XII-deficient plasma.  The capacity to 
activate Hageman factor has been demonstrated to reside in the lipid A region 
of the  LPS molecule.  Activation of Hageman  factor by LPS  contrasts  with 
fluid-phase  activation  (e.g.,  by kallikrein or  trypsin)  in  that  no  cleavage to 
lower molecular weight fragments occurs. High concentrations of LPS inhibit 
the  activity of Hageman  factor, probably  by  a  direct LPS-Hageman  factor 
interaction. 
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